U.S. Markets closed

# TWO MINUTE MONEY: Get paid to spend with cash-back cards

Welcome to Two Minute Money, Yahoo Finance’s new personal finance series offering quick explanations for some the the most important questions involving your money.

There are thousands of credit cards on the market right now. Choosing the right card can feel like a burden. But today we’re going to focus on just one: cash-back.

Here’s the lowdown on cash-back cards: These cards are true to their name, offering a little cash-back for every dollar you spend. Different cards have different terms for calculating just how much you get back.

No credit history? No problem. You’re more likely to get approved for cash-back than another type of rewards card.

Let’s say you spend \$2,000 a month on your credit card. How would that add up with some of the different types of cash-back cards on the market?

Capital Quicksilver One rewards is a great example of a flat rate rewards card. This card gives you 1.5% back of every dollar you spend—no matter what you spend it on. Multiply your monthly spending by a rate of 1.5% (Or .015), Then multiply by 12 months. And get your preliminary cash-back earnings: a total of \$360. That shakes out to \$321 in cash-back a year after fees.

A second type of card offers higher cash-back rates in specific shopping categories. Amex blue cash rewards, for instance, offers 3% cash-back on gasoline and 6% on groceries—with 1% cash-back on all other purchases.

Let’s do the math. Say you spend \$500 a month on groceries, \$200 on gas, and the remaining \$1,300 a month on all other purchases. Add up the categories, subtract the \$95 annual fee, and you get a total of \$493 in cash-back per year.

Some cards offer higher cash-back rates in rotating categories. Chase freedom offers 5% cash-back in a spending category that changes every quarter—with 1% back on all other purchases.

Let’s crunch the numbers. Spend an average of \$500 a month in special categories then spend the remaining \$1,500 on non-category purchases. And your combined cash-back is \$530 a year with no annual fee.

To sum it up:

• The key to picking a cash-back card is knowing your habits.
• Unpredictable spender? Go flat rate.
• Amenable to specific terms? Try out rotating categories.

If you’re still unsure and think you might be interested in a different type of card altogether—check out our points card video later in the week.

Want to be a part of a new Yahoo Finance series? We are looking for people in their 20s and 30s who need a money makeover.  Apply here.

## More from Two Minute Money:

• Finance
Market Realist

### Tesla Stock Is Up 10.2%: What’s Helping It Defy Gravity?

Tesla (TSLA) stock appears to be defying gravity today and is rallying despite the broader market sell-off. Today at 1:08 PM EDT, Tesla stock was up 10.2% from the previous session’s closing price. Earlier today, Citron Research—one of the Tesla bears—surprised the market by turning positive on TSLA for the first time.

### Wall Street is ignoring a risk related to a key part of Nvidia's business, UBS says (NVDA)

Nvidia unveiled its new graphics-card lineup GeForce RTX series in August, which improves the gaming experience through new features. The timing causes a huge risk in Nvidia's chip transition period, RBC says. Wall Street analysts have ignored a major uncertainty in Nvidia's gaming business— a timing risk of its chip transition period, UBS says.

• Finance
Bloomberg

### Companies Say They're Ready to Move Supply Chains From China

U.S. President Donald Trump imposed a 10 percent tariff on \$200 billion of Chinese imports in September -- following an earlier round of tariffs on \$50 billion of goods -- and promised to raise the duty to 25 percent in January. "We’re pro-actively taking action," Todd Bluedorn, chief executive officer of the Texas-based HVAC company, told analysts during an Oct. 22 earnings call.

Motley Fool

### 2 More Marijuana Stocks Are Moving to the NYSE

This year, we've witnessed GW Pharmaceuticals gain approval in the U.S. for the first cannabis-derived drug, and we watched as Vermont legalized recreational marijuana use entirely through the legislative process. This began with Cronos Group at the end of February, when it chose to list its shares on the Nasdaq. It was followed just a few months later by Canopy Growth Corp., which became the first marijuana stock to list on the NYSE.

Motley Fool

### Why Investors Are Paying a Premium for These 3 Biotech Stocks

Amarin stock exploded in September because it looks like Vascepa will become the next go-to drug for this enormous population. During the 8,179-patient Reduce-It trial, patients given Vascepa in addition to their normal statin treatments were 25% less likely to suffer a major cardiovascular event such as a heart attack. Over the past year, Amarin Corporation actually lost \$92 million because sales of Vascepa just haven't kept pace with operating expenses.

Motley Fool

### 5 Deeply Discounted Value Stocks That Haven't Been This Cheap in at Least a Decade

October has been a wake-up call for investors that the stock market won't go up in a straight line, even if we'd like it to. Sure, Bank of America (NYSE: BAC) has seen its stock catapult higher from its Great Recession lows, but its forward P/E of 9.8 would represent a more-than-decade low for the stock.

Benzinga

### A Preview Of Juniper Networks Q3 Earnings

Juniper Networks (NYSE: JNPR) releases its next round of earnings this Tuesday, Oct. 23. Here's Benzinga's essential guide to Juniper Networks' Q3 earnings report. Earnings and Revenue Juniper Networks EPS will likely be near 44 cents while revenue will

Yahoo Finance Video

### MARKETS: Here's why stocks are selling off right now and what a bottom would look like

Live from the floor of the New York Stock Exchange, Yahoo Finance's Jared Blikre joins Seana Smith to discuss the latest market moves.

CNBC

### Here's the tax bite on \$1.6 billion Mega Millions and \$620 million Powerball jackpots

Strategies can be employed to reduce the amount of your win that is taxed, although they are best explored with the help of an experienced tax advisor. While it's anyone's guess who will end up winning the Mega Millions and Powerball jackpots, there's at least one guaranteed recipient of a chunk of the loot — the IRS. With the Mega Millions jackpot at \$1.6 billion and Powerball's top prize at \$620 million, that tax bill will be hefty even if the winner employs strategies to reduce their taxable income.

• News
MarketWatch

### Suze Orman missed the point of retirement, and that’s why she went back to work

Suze Orman did a smackdown of the FIRE (Financial Independence/Retire Early) movement on Paula Pant’s podcast. Coach Carson posted a balanced, informative response, appreciating Suze’s admonition to be sure you have enough for a risk-free retirement. Suze enumerated a string “what can go wrong” scenarios as evidence that early retirement (on less than \$10 million) leaves you vulnerable when life hands you lemons — a whole tree of lemons.

Motley Fool

### Parsing Visa's Big Quarterly Dividend Hike

The ubiquitous financial services player Visa (NYSE: V) isn't exactly an income stock -- its dividend yield has fairly consistently been below 1% for years. Which raises two interesting questions for MarketFoolery host Chris Hill and senior analyst Jason Moser. In this segment from MarketFoolery, they discuss Visa's cash cow structure, its stock repurchases, and the M&A possibilities it thus far seems to be ignoring.

• COL
CNBC Videos

### These stocks may be sacrificed in a cold war with China

Jim Cramer says the escalation in the United States' trade war with China could end in an outright cold war that debilitates parts of the stock market.

• Finance
Market Realist

### What Energy Transfer’s Technical Indicators Suggest

How Energy Transfer Stock Has Fared (Continued from Prior Part) Moving averages Let’s see where Energy Transfer (ET) stock might go from here. Energy Transfer stock is currently trading at \$16.47, almost 6% and 3% below its 50-day and 200-day moving

### The stock market's 'dead cat bounce' is over and the rolling bear market is making a comeback, Morgan Stanley says

The stock market may have bounced back from its sharp sell-off at the beginning of October, but Morgan Stanley says the selling will pick back up soon. The firm expects the S&P 500 to slide back below the 200-day moving average, a key technical level. Tread carefully in tech and consumer discretionary, Morgan Stanley warns.

• News
CNBC

### Here's how much money you should have saved by 50

Fidelity, the nation's largest retirement-plan provider, recommends having the equivalent of six times your annual salary saved. To get to that number, Fidelity recommends saving 15 percent of your annual income. Make sure to invest these funds instead of leaving them in a traditional low-interest savings account.

Motley Fool

### Why These 3 Top Marijuana Stocks Slumped Today

With earnings season hitting a crescendo this week, investors are looking closely at the specific prospects for certain corners of the market, and that's contributing to disparities among the various major benchmarks followed most often by investors. Amid the crosscurrents, marijuana stocks took particularly hard hits, and New Age Beverages (NASDAQ: NBEV), Tilray (NASDAQ: TLRY), and Canopy Growth (NYSE: CGC) were among the worst performers on the day. All three of these stocks have given back some of their gains following the long-awaited legalization of recreational cannabis in the Canadian market last week. In the month leading up to the Oct. 17 start date for legal cannabis sales, New Age Beverages tripled in value, while Tilray had more than doubled since the end of August, and Canopy Growth had seen more modest gains of between 10% and 20%.

Motley Fool

### Why Nektar Therapeutics Crashed 17.2% Today

After delivering a disappointing update on NKTR-214 in cancer patients this summer, Nektar Therapeutics' (NASDAQ: NKTR) shares have been struggling. The company didn't report any news today, so a negative report issued by Plainview LLC this month may be to blamed for its 17.2% tumble today. In February, Bristol-Myers Squibb (NYSE: BMY) inked a blockbuster deal to license rights to NKTR-214 following positive data last year for NKTR-214's use alongside Bristol-Myers' Opdivo.

Benzinga

### Morgan Stanley: 6 Ways Caesars Entertainment Can Create Value

Gaming operator Caesars Entertainment Corporation (NASDAQ: CZR) boasts multiple upside catalysts that imply the stock is undervalued, according to Morgan Stanley. The Analyst Morgan Stanley's Thomas Allen initiated coverage of Caesars Entertainment

Motley Fool

### Why Senseonics Holdings Inc. Is Soaring Today

In response to signing a reimbursement contract with one of the largest insurers in the U.S., shares of Senseonics Holdings (NYSEMKT: SENS), a medical device company focused on blood sugar monitoring, rose 11% as of 10:30 a.m. EDT on Tuesday. Senseonics announced today that Aetna (NYSE: AET) is now offering reimbursement for the company's recently approved Eversense Continuous Glucose Monitoring System (CGM). This is a big deal for Senseonics because Aetna is the third-largest health insurer in the U.S. with more than 22 million lives covered.

• Politics
Bloomberg

### Trump’s Tax Push to Help Middle Class Could Help Top Earners Too

It’s still unclear how Trump will propose to reduce the tax burden on middle-class Americans, but one of the most straightforward ways would be to lower rates by 10 percent for single filers making up to \$82,500. U.S. income tax rates are graduated and income dollars get taxed in chunks as they move up through the brackets -- which means wealthy Americans would also get to apply the reduced rate on their first dollars of income. “A millionaire gets the same size tax cut,” said Kyle Pomerleau, an economist at the conservative Tax Foundation.

• News
MarketWatch

### Dow tumbles nearly 550 points at lows amid corporate outlook, China selloff

It was a punishing start for stocks Tuesday as investors reacted negatively to quarterly results from a handful of blue chips and the cessation of a two-day rebound for China’s embattled stock market, reviving fresh questions about global economic growth prospects. The Dow Jones Industrial Average (DJIA) 548.62 points at its low and remained was recently 460 points, or 1.8%, at 24,862. The S&P 500 (SPX) fell 55 points, or 2%, to 2,696, retreating below a psychological and technical mark at 2,700, while the Nasdaq Composite Index (COMP) slid gave up 177 points, or 2.4%, to 7,291.

Motley Fool

### What the Market Missed in Kinder Morgan Inc.'s Results

Kinder Morgan (NYSE: KMI) can't seem to catch a break these days. Despite its completing what management dubbed a "momentous" quarter, shares of the natural gas pipeline giant barely budged this week. It was a head-scratching outcome considering that its financial results came in well above its guidance, which the market seems to have completely missed.

• Finance
Market Realist

### What to Expect from Bristol-Myers Squibb’s Q3 Earnings

Bristol-Myers Squibb (BMY) is expected to report its third-quarter earnings on October 25. Analysts expect Bristol-Myers Squibb’s revenues to increase 8.87% from \$5.25 billion in the third quarter of 2017 to \$5.72 billion in the third quarte of 2018. In the last four quarters, Bristol-Myers Squibb’s revenue growth has been 3.93%–10.89%.